Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: Biocon - What They Never Told You

Biocon shares rise 3% after Rs 638-crore block deal; Active Pine likely seller

Biocon shares rose after a block deal involving around 1.65 crore shares. Investor Active Pine was reportedly looking to sell up to 1.66 crore shares, or about 1% stake, for around Rs 638 crore at a floor price of Rs 385 per share, implying a discount of up to 1.9%…

The Economic Times

Stocks in news: Biocon, Bank of Baroda, TCS, Sanofi India and Tata Capital

Indian equity markets hit a seven-week low on Tuesday, primarily due to escalating crude oil prices and geopolitical instability that swayed investor morale. Notably, Bank of Baroda announced plans to divest its interest in the NSE, while TCS secured a major contract. Other companies such as Sanofi India and Piramal…

The Economic Times

Biocon shares: Active Pine may divest up to 1% equity worth Rs 638 crore via block deal

Active Pine is likely to sell up to 1.66 crore Biocon shares, worth Rs 638 crore, through a block deal at Rs 385 per share. The development comes alongside Biocon’s Brazil partnership for Pertuzumab under a 10-year programme.

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in Brazil

Biocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis received full allocation under the country’s PDP programme, providing access to around 70% of public-sector demand.

The Economic Times

Biocon signs 10-year Brazil supply deal for Pertuzumab breast cancer drug

In a significant move, Biocon has secured a ten-year contract in Brazil for the distribution of Pertuzumab, made possible through its collaboration with Bahiafarma and Bionovis. This partnership offers exclusive rights to supply the public healthcare sector in Brazil, with plans for phased localization of production. This endeavor aims to…

The Economic Times

Kiran Mazumdar-Shaw and Falguni Nayar: 3 Lessons Indian Women Entrepreneurs Teach Us About Starting Late

Lesson 1: Bet on the gap nobody respectable is fillingChanakya wrote in the Arthashastra that the wise person profits where others see only risk. Falguni Nayar spotted exactly that kind of gap in 2012. Organised beauty retail in India barely existed. Department store cosmetics counters were chaotic, mall kiosks stocked…

Times Life

Biocon shares rise 2% after USFDA approval for Yesintek single-dose prefilled autoinjector

Biocon shares rose after its US subsidiary received supplemental FDA approval for Yesintek single-dose prefilled autoinjectors in two strengths. The approval expands Biocon’s US immunology portfolio, with Yesintek used to treat conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Biocon gets Health Canada nod for Yesintek autoinjector pen

Biocon received Health Canada approval for its Yesintek autoinjector. This new format offers patients a convenient treatment option for psoriasis. The autoinjector is also indicated for psoriatic arthritis and Crohn's disease. This approval strengthens Biocon's immunology product portfolio in Canada. The company aims to increase patient access to affordable medicines…

The Economic Times

MSCI India rejig: Eternal likely to see highest inflows at $648 mn; Lenskart, Groww among Nuvama’s expected inclusions

MSCI’s August India Standard Index review could trigger major passive inflows, with Eternal expected to attract the highest at $648 million, according to Nuvama. The brokerage sees Laurus Labs, Adani Energy Solutions, Lenskart and Groww among likely inclusions, while Balkrishna Industries, SBI Cards and Astral face potential exclusions.

The Economic Times

Ahead of Market: 10 things that will decide stock market action on Wednesday

Indian equities fell sharply as escalating West Asia tensions lifted crude oil prices and weakened the rupee, raising inflation concerns. Sensex and Nifty declined up to 0.7%, while analysts said geopolitical risks overshadowed earnings optimism despite technical support remaining intact.

The Economic Times

Biocon shares jump 6% as Mylan likely exits drugmaker after Rs 3,481 crore stake sale

Biocon shares experienced a significant jump of over 6% on Tuesday. Viatris-owned Mylan intends to sell a substantial stake, exiting the Indian drugmaker. This stake sale represents 5.64% of Biocon's outstanding shares. The offer's floor price was set at a discount to the previous closing price. Block deals totaling nearly…

The Economic Times

Stocks in news: Tata Elxsi, HCL Tech, ICICI Pru AMC, Biocon, SpiceJet

Indian markets closed nearly unchanged after a volatile trading session on Monday. Tata Elxsi and L&T Tech shares are in focus as they announce first quarter results. HCL Tech reported a twenty percent year-on-year net profit growth and declared an interim dividend. ICICI Prudential AMC also saw a twenty-three percent…

The Economic Times

Kiran Mazumdar-Shaw warns against long-term GLP-1 use, urges caution over weight-loss drugs, says 'for those who are not diabetic or clinically obese...'

Nithin Kamath questions India's slow adoption of affordable GLP-1 weight-loss drugs, despite rising obesity. He points to challenges like long-term adherence and physician conservatism. Biocon's Kiran Mazumdar-Shaw weighed in and urged caution, emphasizing diet and exercise as primary options for non-diabetic, non-obese individuals, citing potential long-term side effects of these…

The Economic Times

Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal Manchanda

India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and consumer healthcare. While US FDA approvals for complex generics remain a challenge, innovation and contract manufacturing offer significant future profit pools. Experts anticipate biosimilars could generate substantial revenue, and despite a slow start, GLP-1…

The Economic Times

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Laurus Labs, Biocon, Ather Energy, Lenskart among probable MSCI India Standard Index inclusion candidates, says JM Financial

JM Financial anticipates significant shifts in the MSCI India Standard Index. Laurus Labs and Biocon are flagged as high-probability additions from the Small Cap Index, while Ather Energy and SAIL are medium-probability candidates. SBI Card faces a high probability of exclusion. These potential changes could lead to substantial passive fund…

The Economic Times

Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for Biocon

Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutical companies shift focus to newer weight-loss drugs. Currently the third-largest global insulin provider, Biocon is significantly expanding production. This strategic move addresses a critical gap in the market, particularly…

The Economic Times

Kiran Mazumdar-Shaw shares drone cleaning video, asks startups: 'Where's your innovation?'

Kiran Mazumdar-Shaw, Biocon founder, sparked debate by questioning startup innovation. She shared a video of a drone cleaning windows in Bengaluru. Social media users responded with varied opinions. Some raised concerns about job losses due to automation. Others suggested more advanced drone applications for urban management. The discussion highlights differing…

The Economic Times

“Not Australia…”: Kiran Mazumdar-Shaw says India rejected her brewing career because she was a woman, pushing her to build Biocon

Biocon founder Kiran Mazumdar-Shaw corrected a viral post claiming Australia denied her a master brewer role due to gender. She clarified that it was India that rejected her, prompting her to establish Biocon in 1978. Despite facing significant gender-based discrimination and hiring challenges, Shaw built Biocon into a global biopharmaceutical…

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Vodafone Idea and 6 other stocks hit a 52-week high, rally up to 40% in a month

Despite Sensex closing lower, six BSE 200 stocks including Vodafone Idea, Biocon, and Sun Pharma hit 52-week highs, signaling strong bullish momentum and sustained investor confidence amid broader weakness.

The Economic Times

Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?

Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business improvements, better margins, and strong earnings, the pharma major's market cap surged. Analysts see further upside but advise caution with stop losses due to the steep rise.

The Economic Times

Biocon Q4 Results: Net profit down 57% at Rs 198.6 crore

Biocon Ltd reported a 56.8% drop in Q4 net profit to Rs 198.6 crore, impacted by an Rs 80.4 crore exceptional item. Despite this, consolidated revenue grew to Rs 4,516.6 crore. For FY26, net profit declined to Rs 368.8 crore, though revenue rose to Rs 16,927 crore.

The Hindu

Water woes | BWSSB to save nearly 60 MLD daily through supply cut to big consumers in Bengaluru

The Bangalore Water Supply and Sewerage Board (BWSSB) aims to save 60 MLD of water daily by cutting supply to big consumers in Bengaluru.

The Hindu

Infosys, Biocon, JSW Steel, Shahi Exports donated to JD(S) via electoral bonds

Election Commission reveals donors of Rs 48.75 crore to JD(S) party in Karnataka via electoral bonds.

The Hindu

Cyber frauds misuse BIOCON CEO’s photo to create WhatsApp group

Unknown person misused BIOCON CEO's profile to create WhatsApp group, sent messages to staff to buy gift cards. Srikant Patil received email from person posing as Shreehas Tambe, suspected something fishy and informed higher ups. Police registered case against unknown person under IT Act, cheating and impersonation.

The Hindu

Betting big on Bengaluru

My introduction to Bengaluru (then Bangalore) happened in 1983. I joined Wipro fresh from business school and stayed at the Gautam Hotel. It was ₹70 for a double room. We’d hang out at the Coffee House, The Only Place, The Rice Bowl, and a Chinese rooftop restaurant at Ashoka –…

1 2

People

Chanakya Arthashastra

12 stories

Kumar Gaurav

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.